The combination treatment had a stronger inhibitory effect on both IM-sensitive and IM-resistant CML CD34+ cells than on NBM CD34+ cells (Fig. 5E), and effectively induced apoptosis in CML CD34+ cells (Fig. S5). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.